AIDS and Cancer Virus Program
Rebecca F. Kiser received her B.S. in Biochemistry from VA Tech in 1979 and her
Master’s Degree in 1989 from Hood College in Biomedical Sciences, Immunology Option.
Since 1998, she has served as both as Scientific Program Manager for the AIDS and
Cancer Virus Program (ACVP) and Head of the Specimen Support Core for the ACVP.
In August 1998 an internal ACVP core was created to provide support for processing
and assaying specimens derived from vaccine and pathogenesis studies conducted in
non-human primates. This core, designated the Specimen Support Core (SSC), is charged
with providing the ongoing infrastructure support for non-human primate protocols
and now serves as the “clinical laboratory” equivalent for specimens associated
with AIDS vaccine and pathogenesis studies in non-human primates conducted by ACVP
investigators and collaborators. The SSC receives, accessions, processes, distributes,
and stores blood and tissue derived specimens from macaques under study, and maintains
detailed databases on these specimens, including current inventories of cryo-preserved
samples. The SSC also performs standardized assays including flow cytometry for
these samples. Responsibility for preparation of all anti-retroviral drugs for use
in ACVP and collaborative non-human primate studies also falls to the SSC. The SSC
primarily supports the non-human primate studies of ACVP investigators and their
intramural and extramural collaborators.
- Hatziioannou T, Ambrose Z, Chung NPY, Piatak MJr, Yuan F, Trubey CM, Coalter V,
Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani
VN, Lifson JD, Bieniasz PD: A macaque model of HIV-1 infection. PNAS 106:4425-4429,
- Lifson JD, Rossio JL, Piatak MJr, Bess JJr, Chertova E, Schneider DK, Coalter
V, Poore B, Kiser R, Imming RJ, Scarzello AJ, Henderson LE, Alvord WG, Hirsch VM,
Benveniste RE, Arthur LO: Evaluation of the safety, immunogenicity, and protective
efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with
conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses
- Lifson JD, Piatak M, Rossio JL, Bess J, Chertova E, Schneider D, Kiser R, Coalter
V, Poore B, Imming R, Desrosiers RC, Henderson LE, Arthur LO: Whole inactivated
SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity,
and activity against intrarectal challenge. J Med Primatol 31:205-216, 2002.
- Lifson JD, Rossio JL, Piatak M, Parks T, Li L, Kiser R, Coalter V, Fisher B, Flynn
BM, Czajak S, Hirsch VM, Reimann KA, Schmitz JE, Ghrayeb J, Bischofberger N, Nowak
MA, Desrosiers RC, Wodarz D: Role of CD8+ lymphocytes in control of simian immunodeficiency
virus infection and resistance to rechallenge after transient early antiretroviral
treatment. J Virol 75:10187-10199, 2001.
- Lifson JD, Rossio JL, Arnaout R, Li L, Parks TL, Schneider DM, Kiser RF, Coalter
VJ, Walsh G, Imming RJ, Fisher B, Flynn BM, Bischofberger N, Piatak MJr, Hirsch
VM, Nowak MA, Wodarz D: Containment of SIV infection: Cellular immune responses
and protection from rechallenge following transient post-inoculation antiretroviral
treatment. J Virol 74:2584-2593, 2000.
- Vicky J. Coalter, Research Associate III
- Donald Johnson, Research Associate II
- Adam C. Wiles, Research Associate I
- Rodney W. Wiles, Research Associate I